Coforge Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 26, 2025, 8:14 am

Competitors of Coforge Ltd

All Competitor Stocks of Coforge Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:35 pm

Below is a detailed analysis of the quarterly data for Coforge Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 3,689.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,410.00 Cr. (Mar 2025) to 3,689.00 Cr., marking an increase of 279.00 Cr..
• For Expenses, as of Jun 2025, the value is 3,112.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,883.00 Cr. (Mar 2025) to 3,112.00 Cr., marking an increase of 229.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 577.00 Cr.. The value appears strong and on an upward trend. It has increased from 527.00 Cr. (Mar 2025) to 577.00 Cr., marking an increase of 50.00 Cr..
• For OPM %, as of Jun 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 15.00% (Mar 2025) to 16.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2025) to 64.00 Cr., marking an increase of 31.00 Cr..
• For Interest, as of Jun 2025, the value is 46.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 40.00 Cr. (Mar 2025) to 46.00 Cr., marking an increase of 6.00 Cr..
• For Depreciation, as of Jun 2025, the value is 159.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 125.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 34.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 436.00 Cr.. The value appears strong and on an upward trend. It has increased from 395.00 Cr. (Mar 2025) to 436.00 Cr., marking an increase of 41.00 Cr..
• For Tax %, as of Jun 2025, the value is 18.00%. The value appears to be improving (decreasing) as expected. It has decreased from 22.00% (Mar 2025) to 18.00%, marking a decrease of 4.00%.
• For Net Profit, as of Jun 2025, the value is 356.00 Cr.. The value appears strong and on an upward trend. It has increased from 307.00 Cr. (Mar 2025) to 356.00 Cr., marking an increase of 49.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 9.49. The value appears strong and on an upward trend. It has increased from 7.99 (Mar 2025) to 9.49, marking an increase of 1.50.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:30 am

Growth

Last Updated: September 5, 2025, 2:05 am

Balance Sheet

Last Updated: September 10, 2025, 1:39 pm

Below is a detailed analysis of the balance sheet data for Coforge Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 67.00 Cr.. The value appears strong and on an upward trend. It has increased from 62.00 Cr. (Mar 2024) to 67.00 Cr., marking an increase of 5.00 Cr..
• For Reserves, as of Mar 2025, the value is 6,312.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,565.00 Cr. (Mar 2024) to 6,312.00 Cr., marking an increase of 2,747.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1,070.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 726.00 Cr. (Mar 2024) to 1,070.00 Cr., marking an increase of 344.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 4,823.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,708.00 Cr. (Mar 2024) to 4,823.00 Cr., marking an increase of 3,115.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 12,272.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,061.00 Cr. (Mar 2024) to 12,272.00 Cr., marking an increase of 6,211.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 6,096.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,353.00 Cr. (Mar 2024) to 6,096.00 Cr., marking an increase of 3,743.00 Cr..
• For CWIP, as of Mar 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2024) to 2.00 Cr., marking a decrease of 21.00 Cr..
• For Investments, as of Mar 2025, the value is 146.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 146.00 Cr., marking an increase of 146.00 Cr..
• For Other Assets, as of Mar 2025, the value is 6,028.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,685.00 Cr. (Mar 2024) to 6,028.00 Cr., marking an increase of 2,343.00 Cr..
• For Total Assets, as of Mar 2025, the value is 12,272.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,061.00 Cr. (Mar 2024) to 12,272.00 Cr., marking an increase of 6,211.00 Cr..

Notably, the Reserves (6,312.00 Cr.) exceed the Borrowings (1,070.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Coforge Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 123.01. This value is within the healthy range. It has decreased from 131.56 (Mar 24) to 123.01, marking a decrease of 8.55.
• For Diluted EPS (Rs.), as of Mar 25, the value is 122.03. This value is within the healthy range. It has decreased from 131.56 (Mar 24) to 122.03, marking a decrease of 9.53.
• For Cash EPS (Rs.), as of Mar 25, the value is 203.84. This value is within the healthy range. It has increased from 186.76 (Mar 24) to 203.84, marking an increase of 17.08.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 953.54. It has increased from 586.83 (Mar 24) to 953.54, marking an increase of 366.71.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 953.54. It has increased from 586.83 (Mar 24) to 953.54, marking an increase of 366.71.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,801.30. It has increased from 1,485.28 (Mar 24) to 1,801.30, marking an increase of 316.02.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 277.79. This value is within the healthy range. It has increased from 240.95 (Mar 24) to 277.79, marking an increase of 36.84.
• For PBIT / Share (Rs.), as of Mar 25, the value is 213.87. This value is within the healthy range. It has increased from 189.40 (Mar 24) to 213.87, marking an increase of 24.47.
• For PBT / Share (Rs.), as of Mar 25, the value is 193.74. This value is within the healthy range. It has increased from 169.08 (Mar 24) to 193.74, marking an increase of 24.66.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 139.93. This value is within the healthy range. It has increased from 135.21 (Mar 24) to 139.93, marking an increase of 4.72.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 121.39. This value is within the healthy range. It has decreased from 130.74 (Mar 24) to 121.39, marking a decrease of 9.35.
• For PBDIT Margin (%), as of Mar 25, the value is 15.42. This value is within the healthy range. It has decreased from 16.22 (Mar 24) to 15.42, marking a decrease of 0.80.
• For PBIT Margin (%), as of Mar 25, the value is 11.87. This value is within the healthy range. It has decreased from 12.75 (Mar 24) to 11.87, marking a decrease of 0.88.
• For PBT Margin (%), as of Mar 25, the value is 10.75. This value is within the healthy range. It has decreased from 11.38 (Mar 24) to 10.75, marking a decrease of 0.63.
• For Net Profit Margin (%), as of Mar 25, the value is 7.76. This value is within the healthy range. It has decreased from 9.10 (Mar 24) to 7.76, marking a decrease of 1.34.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.73. This value is below the healthy minimum of 8. It has decreased from 8.80 (Mar 24) to 6.73, marking a decrease of 2.07.
• For Return on Networth / Equity (%), as of Mar 25, the value is 12.73. This value is below the healthy minimum of 15. It has decreased from 22.27 (Mar 24) to 12.73, marking a decrease of 9.54.
• For Return on Capital Employeed (%), as of Mar 25, the value is 14.73. This value is within the healthy range. It has decreased from 25.57 (Mar 24) to 14.73, marking a decrease of 10.84.
• For Return On Assets (%), as of Mar 25, the value is 6.50. This value is within the healthy range. It has decreased from 13.22 (Mar 24) to 6.50, marking a decrease of 6.72.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.00, marking a decrease of 0.09.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.10. This value is within the healthy range. It has decreased from 0.12 (Mar 24) to 0.10, marking a decrease of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.30. It has decreased from 1.56 (Mar 24) to 1.30, marking a decrease of 0.26.
• For Current Ratio (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 1.71, marking an increase of 0.01.
• For Quick Ratio (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 1.71, marking an increase of 0.01.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 61.32. This value exceeds the healthy maximum of 50. It has increased from 57.74 (Mar 24) to 61.32, marking an increase of 3.58.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 40.17. This value is within the healthy range. It has decreased from 41.41 (Mar 24) to 40.17, marking a decrease of 1.24.
• For Earning Retention Ratio (%), as of Mar 25, the value is 38.68. This value is below the healthy minimum of 40. It has decreased from 42.26 (Mar 24) to 38.68, marking a decrease of 3.58.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 59.83. This value is within the healthy range. It has increased from 58.59 (Mar 24) to 59.83, marking an increase of 1.24.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 13.80. This value is within the healthy range. It has increased from 11.86 (Mar 24) to 13.80, marking an increase of 1.94.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.15. This value is within the healthy range. It has increased from 7.65 (Mar 24) to 8.15, marking an increase of 0.50.
• For Enterprise Value (Cr.), as of Mar 25, the value is 55,947.74. It has increased from 34,184.90 (Mar 24) to 55,947.74, marking an increase of 21,762.84.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.64. This value exceeds the healthy maximum of 3. It has increased from 3.72 (Mar 24) to 4.64, marking an increase of 0.92.
• For EV / EBITDA (X), as of Mar 25, the value is 30.11. This value exceeds the healthy maximum of 15. It has increased from 22.96 (Mar 24) to 30.11, marking an increase of 7.15.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. It has increased from 3.70 (Mar 24) to 4.50, marking an increase of 0.80.
• For Retention Ratios (%), as of Mar 25, the value is 38.67. This value is within the healthy range. It has decreased from 42.25 (Mar 24) to 38.67, marking a decrease of 3.58.
• For Price / BV (X), as of Mar 25, the value is 8.49. This value exceeds the healthy maximum of 3. It has decreased from 9.37 (Mar 24) to 8.49, marking a decrease of 0.88.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. It has increased from 3.70 (Mar 24) to 4.50, marking an increase of 0.80.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness